share_log

Lisata Therapeutics Announces US FDA Rare Pediatric Disease Designation Granted To LSTA1 For Treatment Of Osteosarcoma

Lisata Therapeutics Announces US FDA Rare Pediatric Disease Designation Granted To LSTA1 For Treatment Of Osteosarcoma

Lisata Therapeutics 宣佈美國食品藥品管理局授予 LSTA1 罕見兒科疾病稱號,用於治療骨肉瘤
Benzinga ·  03/21 08:02

Lisata Therapeutics Announces US FDA Rare Pediatric Disease Designation Granted To LSTA1 For Treatment Of Osteosarcoma

Lisata Therapeutics 宣佈美國食品藥品管理局授予 LSTA1 罕見兒科疾病稱號,用於治療骨肉瘤

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論